Checkmate Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 61.41 million compared to USD 36.91 million a year ago. Basic loss per share from continuing operations was USD 2.84 compared to USD 4.49 a year ago.
Checkmate Pharmaceuticals, Inc.
Equities
CMPI
US1628181083
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |